Key result
Long-term cardiotoxic effects of antitumor therapy reduce the survival rate and quality of life of patients who suffer from cancer.
Why the study?
Long-term cardiotoxic effects of antitumor therapy reduce survival and quality of life in cancer patients, making early detection a key task in cardio-oncology.
Cardiovascular disease is a leading cause of poor prognosis in cancer survivors, highlighting the need for early detection of long-term cardiotoxic effects of antitumor therapy.
May warrant cardio-oncology surveillance in cancer survivors; leaves open optimal long-term monitoring strategies.
Oncological and cardiovascular diseases (CVD) hold a leading position among the causes of mortality in many countries of the world, including the Russian Federation [1]. In recent years, a decrease in mortality due to oncologic diseases (OD) is noted around the world thanks to early diagnostics, as well as to the development and implementation of new technologies and therapeutic treatment strategies (chemotherapy, targeted and radiation therapy). Among patients with OD who received chemotherapy and radiation therapy, CVD is one of the leading causes of poor prognosis, including lethal outcomes [2-5]. The long-term cardiotoxic effects of antitumor therapy (chemotherapy, radiation therapy) reduce the survival rate and quality of life of patients who suffer from cancer. Thus, early diagnostics and timely detection of the cardiotoxic effects that follow antitumor treatment is one of the main tasks of cardio-oncology.
No takes yet. Share an insight, caveat, or question.
Kazantseva et al. (2019) conducted a review in Oncological diseases and cardiovascular diseases. Antitumor therapy (chemotherapy, targeted and radiation therapy) was evaluated. Long-term cardiotoxic effects of antitumor therapy reduce the survival rate and quality of life of patients who suffer from cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: